News

Debiopharm signs license and supply agreement with Medical Futures Inc. for the Canadian distribution rights to SANVAR® IR.

The time has come for breast cancer risk assessment, counseling and genetic testing to move from cancer specialists to the realm of primary care, according to a presentation at the AAAS annual meeting.

The technology acquired consist a platform technology referred to by MDC as DIAAD™ and certain monoclonal antibody candidates to detect and treat cancer.

NCI scientists have discovered an antibody that neutralizes two highly infectious viruses classified as henipaviruses.

Biomoda and Medical Acoustics will collect lung sputum samples in an upcoming clinical study that will use Biomoda's proprietary testing technology for detection of early lung cancer.

New agreement provides for development and promotion of OraQuick® HCV test outside the United States.

Vermillion obtains exclusive rights the development of biomarkers that can be applied toward disease detection, classification and monitoring of prevalent cancers.

The 2008 revision of the WHO document on the classification of CMPDs has incorporated new information on the molecular pathogenesis of BCR–ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.

The company has entered into an agreement with Ortho-Clinical Diagnostics to license certain 20/20 intellectual property relating to a blood test for the early detection of lung cancer.

LabCorp enters into an exclusive license agreement to commercialize Duke's new blood-based assay for early detection of lung cancer.